P121 Effectiveness of intracranial stenting procedure in improving clinical outcome and reducing recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis (ICAS)

<h3>Introduction</h3> Stroke is a leading cause of mortality and morbidity worldwide. ICAS accounts for 10- 15% of ischemic stroke in Western countries. <h3>Aim of Study</h3> To demonstrate the effectiveness of intracranial stenting in improving primary and secondary outcome and reducing recurrent stroke in ICAS. <h3>Methods</h3> We included all intracranial stenting procedures performed in patients with symptomatic ICAS between 2022 and 2023. We analyzed periprocedural complications, 30-days clinical improvement and death rates, 1 year rates of clinical improvment, stent patency and recurrent stroke. Follow-up at 6 and 12 months was performed by DSA and neurological examination. <h3>Results</h3> We enrolled 29 patients with TIA or symptomatic ischemic stroke related to ICAS, with a mean age of 65.7 years. Two procedures required the deployment of 2 stents for a total of 31 stents. Of the 29 patients, 18 were treated acutely (62.1%), 11 electively (37.9%). We deployed 10 (32.3%) balloon-expandable stents and 21 (67.7%) self-expandable stents. We encountered two periprocedural complications: a mild reperfusion hemorrhage and a stent occlusion 48 hours after the procedure, which was resolved deploying an additional stent; both cases had no neurological sequelae. The mortality and clinical improvement rates at 30 days were 6.9% and 51%, respectively. One-year follow-up documented 62% rate of clinical improvement, 100% stent patency and 2 new ischemic events. One patient died during follow-up from unrelated causes <h3>Conclusion</h3> Intracranial Stenting for ICAS is a safe and effective procedure to improve patient’s clinical outcome in the acute phase and reduce recurrent stroke. <h3>Disclosure of Interest</h3> no.